{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:03:51Z","timestamp":1780632231584,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s12149-019-01428-8","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T18:02:46Z","timestamp":1575568966000},"page":"163-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Contribution of 5th minute and 2nd hour images to standard imaging in (68Ga)PSMA 11 PET\/CT"],"prefix":"10.1007","volume":"34","author":[{"given":"Canan","family":"Can","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8168-136X","authenticated-orcid":false,"given":"Halil","family":"Komek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"1428_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1428_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.eururo.2016.05.043","volume":"70","author":"MC Wong","year":"2016","unstructured":"Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862\u201374.","journal-title":"Eur Urol"},{"key":"1428_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMe1103829","volume":"365","author":"AV D\u2019Amico","year":"2011","unstructured":"D\u2019Amico AV. Risk-based management of prostate cancer. N Engl J Med. 2011;365:169\u201371.","journal-title":"N Engl J Med"},{"key":"1428_CR4","first-page":"85","volume":"7","author":"M Mansbridge","year":"2019","unstructured":"Mansbridge M, Chung E, Rhee H. The use of MRI and PET imaging studies for prostate cancer management: brief update, clinical recommendations, and technological limitations. Med Sci (Basel). 2019;7:85.","journal-title":"Med Sci (Basel)"},{"key":"1428_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11934-016-0575-5","volume":"17","author":"L Lindenberg","year":"2016","unstructured":"Lindenberg L, Choyke P, Dahut W. Prostate cancer imaging with novel PET tracers. Curr Urol Rep. 2016;17:18.","journal-title":"Curr Urol Rep"},{"key":"1428_CR6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1053\/j.semnuclmed.2016.07.006","volume":"46","author":"K Bouchelouche","year":"2016","unstructured":"Bouchelouche K, Turkbey B, Choyke PL. PSMA PET and radionuclide therapy in prostate cancer. Semin Nucl Med. 2016;46:522\u201335.","journal-title":"Semin Nucl Med"},{"key":"1428_CR7","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926\u201337.","journal-title":"Eur Urol"},{"key":"1428_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"1428_CR9","doi-asserted-by":"publisher","first-page":"e0164392","DOI":"10.1371\/journal.pone.0164392","volume":"18","author":"S L\u00fctje","year":"2016","unstructured":"L\u00fctje S, Blex S, Gomez B, Schaarschmidt BM, Umutlu L, Forsting M, et al. Optimization of acquisition time of 68Ga- PSMA-ligand PET\/MRI in patients with local and metastatic prostate cancer. PLoS ONE. 2016;18(11):e0164392.","journal-title":"PLoS ONE"},{"key":"1428_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00259-016-3578-z","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, et al. Early dynamic imaging in (68)Ga-PSMA-11 PET\/CT allows discrimination of urinary bladder activity and prostate cancer lesions. Eur J Nucl Med Mol Imaging. 2017;44:765\u201375.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR11","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","volume":"26","author":"T Derlin","year":"2016","unstructured":"Derlin T, Weiberg D, von Klot C, Wester HJ, Henkenberens C, Ross TL, et al. (68)Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol. 2016;26:4345\u201353.","journal-title":"Eur Radiol"},{"key":"1428_CR12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1097\/MNM.0000000000000290","volume":"36","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, et al. Evaluation of PSMA PET\/CT imaging using a68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun. 2015;36:582\u20137.","journal-title":"Nucl Med Commun"},{"key":"1428_CR13","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1007\/s00259-016-3424-3","volume":"43","author":"CH Pfob","year":"2016","unstructured":"Pfob CH, Ziegler S, Graner FP, K\u00f6hner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR14","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Hetzheim H, K\u00fcbler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611\u201320.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","volume":"43","author":"C-O Sahlmann","year":"2016","unstructured":"Sahlmann C-O, Meller B, Bouter C, Ritter CO, Str\u00f6bel P, Lotz J, et al. Biphasic 68Ga-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:898\u2013905.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR17","first-page":"779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, M\u00fcller M, Bauder-W\u00fcst U, Remde Y, Sch\u00e4fer M, et al. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharm Basel Switz. 2014;7:779\u201396.","journal-title":"Pharm Basel Switz"},{"key":"1428_CR18","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00259-019-04361-0","volume":"46","author":"M Abufaraj","year":"2019","unstructured":"Abufaraj M, Grubm\u00fcller B, Zeitlinger M, Kramer G, Seitz C, Haitel A, et al. Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET\/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2019;46:2169\u201377.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR19","first-page":"100","volume":"38","author":"F \u00d6z\u00fclker","year":"2019","unstructured":"\u00d6z\u00fclker F. Efficacy of early imaging with 68Ga-PSMA-I&T in the discrimination of pelvic lesions in prostate cancer patients. Rev Esp Med Nucl Imagen Mol. 2019;38:100\u20135.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"1428_CR20","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1007\/s00259-014-2713-y","volume":"41","author":"CM Zechmann","year":"2014","unstructured":"Zechmann CM, Afshar-Oromieh A, Armor T, Stubbs JB, Mier W, Hadaschik B, et al. Radiation dosimetry and first therapy results with a (124)I\/(131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1428_CR21","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.2967\/jnumed.117.192476","volume":"58","author":"TA Hope","year":"2018","unstructured":"Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, et al. Impact of [68Ga]PSMA-11 PET on management in patients with biochemically recurrent prostate cancer. J Nucl Med. 2018;58:1956\u201361.","journal-title":"J Nucl Med"},{"key":"1428_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s11307-018-1263-2","volume":"21","author":"M Hohberg","year":"2019","unstructured":"Hohberg M, Kobe C, T\u00e4ger P, Hammes J, Schmidt M, Dietlein F, et al. Combined early and late [68Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low PSA levels. Mol Imaging Biol. 2019;21:558\u201366.","journal-title":"Mol Imaging Biol"},{"key":"1428_CR23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.2967\/jnumed.116.183483","volume":"58","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Sattler LP, Mier W, Hadaschik BA, Debus J, Holland-Letz T, et al. The clinical impact of additional late PET\/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. Nucl Med. 2017;58:750\u20135.","journal-title":"Nucl Med"},{"key":"1428_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/RLU.0000000000001589","volume":"42","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, Mamach M, Wilke F, von Klot CA, Henkenberens C, Thackeray JT, et al. Multiple time-point 68Ga-PSMA I&T PET\/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging. Clin Nucl Med. 2017;42:286\u201393.","journal-title":"Clin Nucl Med"},{"key":"1428_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","volume":"361","author":"RP Baughman","year":"2003","unstructured":"Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111\u20138.","journal-title":"Lancet"},{"key":"1428_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11307-016-0945-x","volume":"18","author":"V Prasad","year":"2016","unstructured":"Prasad V, Steffen IG, Diederichs G, Makowski MR, Wust P, Brenner W. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol. 2016;18:428\u201336.","journal-title":"Mol Imaging Biol"},{"key":"1428_CR27","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2967\/jnumed.115.164442","volume":"57","author":"T Pyka","year":"2016","unstructured":"Pyka T, Weirich G, Einspieler I, Maurer T, Theisen J, Hatzichristodoulou G, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suggestive lung lesions in patients with prostate cancer. J Nucl Med. 2016;57:367\u201371.","journal-title":"J Nucl Med"},{"key":"1428_CR28","first-page":"65","volume":"36","author":"T Elri","year":"2017","unstructured":"Elri T, Aras M, Salihoglu YS, Erdemir RU. Cabuk MA potential pitfall in the use of 68Ga-PSMA PET\/CT: anthracosis. Rev Esp Med Nucl Imagen Mol. 2017;36:65\u20136.","journal-title":"Rev Esp Med Nucl Imagen Mol"},{"key":"1428_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40644-018-0175-3","volume":"18","author":"Z Keidar","year":"2018","unstructured":"Keidar Z, Gill R, Goshen E, Israel O, Davidson T, Morgulis M, et al. 68Ga-PSMA PET\/CT in prostate cancer patients\u2014patterns of disease, benign findings and pitfalls. Cancer Imaging. 2018;18:39.","journal-title":"Cancer Imaging"},{"key":"1428_CR30","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4103\/ijnm.IJNM_81_18","volume":"33","author":"D Malik","year":"2018","unstructured":"Malik D, Soo A, Mittal BR, Singh H, Basher RK, Shukla J, et al. Nonspecific uptake of 68Ga-prostate specific membrane antigen in diseases other than prostate malignancy on positron emission tomography\/computed tomography imaging: a pictorial assay and review of literature. Indian J Nucl Med. 2018;33:317\u201325.","journal-title":"Indian J Nucl Med"},{"key":"1428_CR31","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1097\/RLU.0000000000002161","volume":"43","author":"P Verma","year":"2018","unstructured":"Verma P, Malhotra G, Agrawal R, Sonavane S, Meshram V, Asopa RV. Evidence of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET\/CT. Clin Nucl Med. 2018;43:e265\u2013e268268.","journal-title":"Clin Nucl Med"},{"key":"1428_CR32","doi-asserted-by":"publisher","first-page":"9867","DOI":"10.18632\/oncotarget.23984","volume":"9","author":"B Heitk\u00f6tter","year":"2018","unstructured":"Heitk\u00f6tter B, Steinestel K, Trautmann M, Gr\u00fcnewald I, Barth P, Gevensleben H, et al. Neovascular PSMA expression is a common feature in malignant neoplasms of the thyroid. Oncotarget. 2018;9:9867\u201374.","journal-title":"Oncotarget"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-019-01428-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-019-01428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T01:44:15Z","timestamp":1607046255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-019-01428-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1428"],"URL":"https:\/\/doi.org\/10.1007\/s12149-019-01428-8","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"20 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}